Long-term safety of canakinumab in patients with systemic juvenile idiopathic arthritis: 5-year results from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry

Abstract Background Systemic juvenile idiopathic arthritis (SJIA) is a severe form of juvenile idiopathic arthritis characterized by fever, rash, chronic arthritis, and systemic inflammation. The introduction of biologics has improved the treatment options for SJIA. Canakinumab selectively inhibits...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Colleen Correll, Alis Burciu, Amita Bansal, Anne Dennos, Deepak Narayanswamy, Elodie Aubrun, Laura E. Schanberg, Li Yuhan, Rahel Schneider, Stephen Balevic, Yukiko Kimura, Timothy Beukelman, for the CARRA Registry investigators
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	BMC 2025-10-01
Seri Bilgileri:	Pediatric Rheumatology Online Journal
Konular:	Systemic juvenile idiopathic arthritis Canakinumab CARRA registry Safety
Online Erişim:	https://doi.org/10.1186/s12969-025-01144-w
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!